Communication between health-care professionals and individuals with cancer regarding the effects of treatment on sexual ...

The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

A study found a "significant" link between the frequency of chest X-ray referrals and improved survival rates for lung cancer ...

Dukhi Hong, 84, has confounded medics to far exceed their six month prognosis following her diagnosis with small cell lung ...

Due to the destructive nature of COPD on patients’ lungs and well-being, timely diagnosis is key, and integrating spirometry ...

OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...

This week Bobbi Conner talks with Dr. Miriam Alexander about advances in lung cancer treatment in recent years. Dr. Alexander ...

Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, all while providing a consistent efficacy ...